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Abstract
The overexpression of estrogen receptor-beta (ER-β) and the cyclooxygenase-2 (COX-2) 
enzyme coupled with the absence of expression of progesterone receptors (PR) is critical to the 
pathogenesis of endometriosis and adenomyosis associated pain.  DLBS1442, a novel bioactive 
extract of Phaleria macrocarpa, exerts its action by downregulating the overexpressed ER-β and 
COX-2 products and up-regulating PR gene expression. This pilot study was conducted to evaluate 
the effectiveness of DLBS1442 treatment in alleviating endometriosis- and/or adenomyosis-related 
pain. Ten endometriosis and/or adenomyosis patients were recruited consecutively at Yasmin 
Clinic Dr. Cipto Mangunkusumo General Hospital in January - March 2013. Pain associated with 
menses, including pre-menstrual pain, dysmenorrhea, dyschezia and dysuria, was measured 
using the visual analog scale (VAS) at each of the next three menstrual cycles. Patients reporting 
one or more pain symptoms with a VAS score ≥ 4 were given 100 mg of DLBS1442 three times 
daily for 12 weeks. VAS score reduction was noted in the first post-treatment menstrual cycle 
(approximately 5.3 weeks after treatment initiation) and VAS scores continued to decline over 
the final two cycles. DLBS1442 was effective in alleviating endometriosis- and/ or adenomyosis-
related pain, as demonstrated by early pain reduction as evaluated using the VAS. 
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Efektivitas Ekstrak Bioaktif Phaleria macrocarpa pada Masalah Nyeri 
Terkait Endometriosis dan/ atau Adenomiosis
Abstrak
Over-ekspresi reseptor estrogen beta (ER-β) dan enzim siklo-oksigenase-2 (COX-2) akan 
menekan ekspresi reseptor progesteron (PR) di endometrium; hal tersebut penting dalam 
patogenesis endometriosis dan adenomiosis. DLBS 1442, ekstrak bioaktif Phaleria macrocarpa, 
bekerja dengan menekan over-ekspresi ER-β dan COX-2 serta meningkatkan regulasi ekspresi 
gen PR. Studi awal dilakukan untuk mengevaluasi efektivitas pengobatan DLBS1442 pada 
masalah nyeri terkait endometriosis dan/ atau adenomiosis. Sepuluh penderita endometriosis dan/ 
atau adenomiosis di klinik Yasmin RSCM pada bulan Januari - Maret 2013 yang memiliki keluhan 
nyeri diikutsertakan dalam penelitian ini. Dilakukan penilaian skor visual analog scale (VAS) untuk 
keluhan nyeri pre-menstruasi, dismenorea, diskezia dan disuria setiap 3 siklus menstruasi. Pasien 
yang memiliki keluhan satu atau dua gejala nyeri dengan skor VAS > 4 diberikan DLBS1442 
sebanyak 3 x 100 mg sehari selama 12 minggu. Penurunan skor VAS diperoleh pada siklus pertama 
menstruasi pascapengobatan (sekitar 5,3 minggu setelah inisiasi pengobatan) dan penurunan 
skor VAS terus berlanjut setelah melewati 2 siklus terakhir pengobatan. DLBS 1442 efektif dalam 
mengatasi masalah nyeri pada endometriosis dan/ atau   adenomiosis.
Kata Kunci: DLBS 1442, dismenorea, endometriosis, adenomiosis 
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Introduction
Endometriosis is a chronic inflammatory disease 
characterized by the presence of endometrium-like 
tissue outside the uterine cavity.1 Gynecological 
disorders are estimated to occur in 176 million 
women worldwide and in one of 10 women of 
reproductive age.2,3 Women with endometriosis 
commonly experience reduced quality of life due 
to pain symptoms, including premenstrual pain, 
dysmenorrhea, dysuria and dyschezia. The pain 
may continue for many years and may cause 
physical weakness as well as psychological, social 
and functional disability.4,5
The pathogenesis and pathophysiology of 
endometriosis is not fully understood. However, 
overexpression of estrogen receptor-b (ER-b) in 
endometriosis tissue is thought to contribute to the 
initiation and progression of endometriosis-related 
pain.6 Increased expression of ER-b will in turn 
suppress the expression of estrogen receptor-a (ER-
a), increasing the ER-b/ER-a ratio. Overexpression of 
ER-b also induces the suppression of the progesterone 
receptor and stimulates cyclooxygenase-2 (COX-2) 
activity, contributing to progesterone resistance and 
an inflammatory reaction.7 Based on these findings, 
drugs that regulate ER-b and maintain the normal 
ER-b/ER-a ratio are promising potential therapies to 
prevent the progesterone resistance and inflammation 
associated with endometriosis-related pain.
DLBS1442 is a proprietary and standardized 
bioactive extract of Phaleria macrocarpa, an 
Indonesian medicinal plant natively known as 
‘mahkota dewa’ (the crown of god). In a previous pre-
clinical study, DLBS1442 demonstrated a capacity to 
down-regulate ER-b, COX-2 and phospholipase-A2 
(cPLA2) gene expression. DLBS1442 was also 
demonstrated in-vitro up-regulation of progesterone 
receptor gene expression.8,9 A previous clinical 
study by Tjandrawinata et al9 showed that 
DLBS1442 was well-tolerated by subjects with pre-
menstrual syndrome and was effective in relieving 
dysmenorrhea, abdominal pain and other symptoms 
related to premenstrual syndrome. Based on those 
findings, we conducted this case study to assess 
the effectiveness of DLBS1442 as a treatment of 
choice for pain related to endometriosis and/ or 
adenomyosis as primarily measured by the VAS. 
Methods
We observed 10 consecutive patients 
presenting for treatment at Yasmin Infertility Clinic 
Dr. Cipto Mangunkusumo General Hospital Jakarta 
during January - March 2013.  Selected patients were 
between 18-45 years old, not pregnant or breast-
feeding and had not used hormonal contraceptives 
within the last three months. The patients’ chief 
complaint was pain during their menstrual periods 
(i.e., dysmenorrhea), which could be accompanied 
by pre-menstrual pain, dysuria and/or dyschezia. All 
the patients have history of endometriosis and/ or 
adenomyosis surgery within 2 years.  Transvaginal 
ultrasonography (ALOKATM, Pro-Sound SSD 3500 
plus), a relatively effective and practical diagnosing 
tool for endometrioma and/ or adenomyosis was 
performed on the 10 patients. Patients did not have 
any plan to receive laparoscopy or other surgeries 
in the next 12 weeks.
After the diagnosis was confirmed, patients 
were asked to rate their pain on the 10 point VAS, 
with zero indicating an absence of pain and 10 
indicating the most severe pain. Patients reporting 
one or more pain symptoms with a VAS score ≥ 
4 were given 100 mg of DLBS1442 three times 
daily for 12 weeks. The VAS score for each pain 
symptom was evaluated at each of the next three 
menstrual cycles.
Results
Of the 10 patients (21-42 years old), two 
patients were diagnosed with adenomyosis and 
eight patients were diagnosed with endometrioma 
measuring 3 - 8 cm in diameter (Table 1).
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Table 1. Duration of VAS Reduction of Dysmenorrhea 
Initial 
Patient
Age
(years) Diagnosis
Duration of reduction of 
dysmenorrhea symptoms 
on the VAS 
1 29         Endometrioma 4 weeks
2 37 Endometrioma 6 weeks
3 40         Adenomyosis 6 weeks
4 31 Endometrioma 7 weeks
5 37 Endometrioma 5 weeks
6 38         Adenomyosis 4 weeks
7 21 Endometrioma 8 weeks
8 25 Endometrioma 2 weeks
9 35 Endometrioma 7 weeks
10 42 Endometrioma 4 weeks
Pain scores on the VAS were found to 
decrease during the first post-treatment menstrual 
cycle and continued to decline with each 
subsequent menstrual cycle. On average, decline 
in dysmenorrhea pain as measured by VAS score 
started 5.3 weeks after the initiation of DLBS1442 
treatment.
After 12 weeks of DLBS1442 treatment, the 
median VAS score for dysmenorrhea was reduced 
from baseline by 4.5 points, while scores for pre-
menstrual pain, menstrual dyschezia and menstrual 
dysuria were reduced from baseline by 2, 1 and 0.5 
points respectively (Table 2). The decline in VAS score 
for each pain symptom is demonstrated in Figure 1.
Table 2. Reduction in Each Pain Symptom on VAS during Three Menstrual Cycles 
Type of pain
VAS (median)
n = 10  Median reduction 
in VAS score per 
cycle over three 
menstrual cycles
(Min-Max)
Before 
treatment 
with 
DLBS1442 
(Min-Max)
After treatment with DLBS1442
Cycle 1 
(Min-Max)
Cycle 2 
(Min-Max)
Cycle 3 
(Min-Max)
Dysmenorrhea 6.5 (4-10) 5 (1-8) 3 (0-8) 2 (0-3) 5 (3-8)
Pre-menstrual 2 (0-10) 0 (0-9) 0 (0-5) 0 (0-5) 1 (0-10)
Dyschezia 1 (0-9) 0 (0-1) 0 (0-0) 0 (0-0) 1 (0-9)
Dysuria 0.5 (0-6) 0 (0-6) 0 (0-2) 0 (0-0) 0.5 (0-6)
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Figure 1.  After DLBS1442 treatment, VAS scores for each pain symptoms decreased 
in the first menstrual cycle and continued to decline during the second and 
third cycles.
Discussion
Medical management of endometriosis 
primarily aims to delay disease progression and 
alleviate symptoms. Aside from infertility, the most 
debilitating symptom in women with endometriosis 
is pain manifested as severe dysmenorrhea, 
dyspareunia, chronic pelvic pain, dysuria or 
dyschezia. These symptoms also tend to worse 
with repeated menstrual cycles.10,11 Therefore, pain 
relief has been one of the major goals of therapies for 
endometriosis. The most widely utilized treatment 
modalities are expectant management, surgery, 
and hormonal therapy.12 Hormonal therapy is widely 
used, as endometriosis is an estrogen-dependent 
condition.10 For endometriosis-associated pain, 
standard first-line medical therapies include non-
steroidal anti-inflammatory drugs (NSAIDs), oral 
contraceptive (combination estrogens/progestins) 
or progestogens (e.g., medroxyprogesterone 
acetate and norethisterone).1-3,13,14 Failing these 
therapies, danazol or GnRH-analogue therapy 
(goserelin, nafarelin, buserelin, leuprorelin) 
is indicated, preferably in combination with 
simultaneous addition of estrogen–progestogen 
add-back therapy. However, if the physician 
believes that laparoscopy is required to confirm 
or reestablish the diagnosis, then operative 
laparoscopy with elimination of visible endometriotic 
implants is advisable.14 
Although most patients receiving currently 
available medical therapy report symptomatic 
improvement (pain relief) and disease regression, 
recurrence rates and adverse events are still 
relatively high.12,18 Such medical therapies are also 
ineffective in improving fertility rates. Hormonal-
based treatment will further delay conception as they 
induce hormonal imbalances. The aim of hormonal 
drug therapy is to reduce estrogen levels, shutting 
down the normal hormonal cycle of stimulation 
and bleeding. When in a hypo-estrogenic state, 
the endometrial deposits shrink down and become 
inactive. Thus, hormonal medication suppresses 
but does not remove endometriosis and is effective 
only for short term management of symptoms. 
Active endometriosis returns gradually over one to 
two years after cessation of drug therapy.12,15-18 
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Vercellini et al showed that continuous 
use of a combined oral contraceptive pill for 
24 months effectively reduced endometriosis-
related pain intensity by 45.95% in patients with 
endometriosis.17 Progestin-only pills effectively 
alleviated endometriosis-related pain and reduced 
recurrence rate after surgical treatment with no 
significant difference in results compared with 
combined oral contraceptive therapy.18 
Additionally, Strowitzki et al19 showed that 
treating patients with endometriosis with a regimen 
of dienogest 2 mg / day for 24 weeks led to a 
reduction in the mean VAS pain score by 4.75. 
Similarly, a reduction of 4.6 in VAS pain score was 
reported in patients receiving a regimen of 3.75 mg 
of leuprolide acetate depot treatment every four 
weeks. As high as a six-point reduction on VAS for 
endometriosis-related pain was reported by Petta 
et al20 in a study using levonorgestrel-releasing 
intrauterine (LNG-IUS) therapy for six months. 
However, this method should not used in women 
who have never had sexual intercourse. 20
Non-steroidal anti-inflammatory drugs have 
widely been studied for the treatment of dysmenor-
rhea and are proven to be effective through inhibi-
tion of cyclooxygenase.21 However, NSAIDs have 
significant adverse reactions, including gastric ulcer 
and the potential to cause an anti-ovulatory effect 
when taken mid-menstrual cycle.1,21,22
Given the available literature on this topic, 
it is necessary to search for a novel agent with 
high efficacy in alleviating endometriosis-related 
symptoms, a relatively more desirable safety 
profile and more durable effectiveness. In this 
study, DLBS1442 demonstrated its effectiveness 
in reducing endometriosis and/ or adenomyosis 
associated pain. It is likely that DLBS1442 exerts 
it effects through triple mechanisms of action 
as demonstrated in a previous in-vitro study, 
i.e. by down-regulating the gene expression of 
ER-b, COX-2 and phospholipase-A2 (cPLA2) 
and up-regulating progesterone receptor gene 
expression.8,9 Through these mechanisms, 
DLBS1442 with its anti-inflammatory activity can 
reduce endometriosis and/ or adenomyosis-
associated pain without inducing a systemic hypo-
estrogenic state. Therefore, no patients in this 
study reported adverse effects related to hormonal 
imbalance, such as disturbed menstrual cycles, 
flushing or weight gain. The promising results 
of this case study justify further larger clinical 
studies to confirm the efficacy of DLBS1442 in 
suppressing endometriosis-associated pain as well 
as in delaying disease progression in patients with 
endometriosis and / or adenomyosis.
Conclusion
This case study showed that a regimen of 100 
mg of DLBS1442 three times daily in patients with 
endometriosis and or adenomyosis was effective in 
alleviating disease-related pain as demonstrated 
by early reduction in VAS scores for dysmenorrhea, 
pre-menstrual pain, menstrual dyschezia and 
dysuria. The pain intensity declined continuously 
with each subsequent menstrual cycle.
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